Sindrome de disfuncion cognitiva (demencia en perros y gatos)

Qué podría notar

• Se pierde o se queda trabado en lugares conocidos: se para en una esquina, mira la pared, o va al lado equivocado de la puerta
• Camina sin rumbo, esta inquieto o llora de noche, y duerme mucho mas de dia (ese cambio de dia y noche es lo primero que muchas familias notan)
• Maulla fuerte de noche. Fue la senal mas reportada en los gatos con disfuncion cognitiva (40% de los gatos afectados en una encuesta)
• Hace sus necesidades dentro de la casa, o el gato lo hace fuera de la caja de arena, cuando antes era muy limpio
• Muestra menos interes en saludarte, en las caricias o en jugar. O al contrario, se vuelve mucho mas pegajoso y se angustia al quedarse solo
• Olvida rutinas, su nombre u ordenes que ya sabia, o parece no oirte ni verte
• Se choca con las cosas, duda en los escalones, o tropieza con muebles que siempre han estado ahi
• Come menos, o se queda parado frente al plato como si no supiera que hacer

Estándar de atención

1. Work up and treat the mimics before treating the brain - in both species

   Aprobado / respaldado por guías

   Every sign on the DISHAA list is also produced by something else in a senior pet. In cats the mandatory short list is osteoarthritic pain, chronic kidney disease, hyperthyroidism and systemic hypertension; hypertension in cats is usually secondary to CKD or hyperthyroidism, causes ocular, cardiac, renal and brain target-organ damage, and amlodipine besylate is the treatment of choice. In dogs the short list is pain, hypothyroidism, hyperadrenocorticism, hepatic disease, intracranial disease and sensory loss. This step is not a formality: it is the step most likely to change the pet's life, and skipping it is how a treatable disease gets labelled dementia. Order of operations for a pet with house-soiling: rule out pain, rule out urinary and GI disease, then consider cognitive decline, then treat as behaviour.

   Productos nombrados: Amlodipine besylate is named by ISFM as the treatment of choice for feline hypertension. Telmisartan (Semintra, NADA 141-501) is FDA-approved with the verbatim indication "SEMINTRA is indicated for the control of systemic hypertension in cats." Methimazole-class antithyroid therapy, radioiodine and thyroidectomy are the feline hyperthyroidism options. No canine dose or product from this step transfers to cats.

   2023 AAHA Senior Care Guidelines describe a systematic, evidence-guided assessment of healthy and unhealthy senior dogs and cats and explicitly address the client misconception that decline is unavoidable old age (dog and cat). 2021 AAFP Feline Senior Care Guidelines make blood pressure a minimum diagnostic in senior cats and treat pain as its own syndrome to be considered in every senior cat (cat). ISFM hypertension guidelines are a formal practice guideline (cat).

   Dhaliwal R, Boynton E, Carrera-Justiz S, et al. 2023 AAHA Senior Care Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2023;59(1):1-21. PMID 36584321. DOI 10.5326/JAAHA-MS-7343; Ray M, Carney HC, Boynton B, et al. 2021 AAFP Feline Senior Care Guidelines. J Feline Med Surg. 2021;23(7):613-638. PMID 34167339. DOI 10.1177/1098612X211021538; Taylor SS, Sparkes AH, Briscoe K, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. J Feline Med Surg. 2017;19(3):288-303. PMID 28245741. DOI 10.1177/1098612X17693500

2. DOGS ONLY: selegiline hydrochloride (Anipryl) - the only FDA-approved drug for this disease in any species

   Aprobado / respaldado por guías

   Label indication, verbatim from the FDA Freedom of Information Summary: "Anipryl tablets are indicated for the control of clinical signs associated with canine Cognitive Dysfunction Syndrome (CDS)." Recommended dosage, verbatim: "0.5 -1.0 mg/kg once daily, preferably administered in the morning. Initially, dogs should be dosed to the nearest whole tablet. Adjustments should then be made based on response and tolerance to the drug." Report the pivotal numbers honestly, because they are modest and the placebo response was large. In 199 client-owned dogs (181 evaluable at 4 weeks) randomised to placebo, 0.2 mg/kg or 1.0 mg/kg for the first 4 weeks, improvement at 1.0 mg/kg versus placebo was: sleep pattern 52.7% vs 16.7% (p = 0.001), activity 54.7% vs 28.6% (p = 0.012), house training 34.8% vs 26.3% (p = 0.030, and non-monotonic - the 0.2 mg/kg group scored 38.9%). Three of six domains did NOT reach significance: orientation 55.2% vs 35.5% (p = 0.098), responsiveness 52.1% vs 41.8% (p = 0.499), greeting 32.6% vs 25.0% (p = 0.584). FDA's own verbatim conclusion: "Anipryl administered at 1.0 mg/kg once daily was shown to provide safe and effective control of clinical signs associated with CDS in pet dogs. The onset, duration and magnitude of response varied with individual dogs." And the durability caveat, verbatim: "The duration of effect may be as short as 8 weeks in about 50% of the cases." A widely quoted 77.2% improvement figure at day 60 comes from an OPEN-LABEL, uncontrolled study of 641 dogs and must never be presented as a controlled efficacy result. Anipryl is prescription-only because, in FDA's words, "professional expertise is required for the diagnosis of clinical signs associated with cognitive dysfunction syndrome and for the monitoring of adverse events and response to therapy." Selegiline is NOT approved for cats and canine dosing must not be carried across.

   Productos nombrados: Selegiline hydrochloride (Anipryl), NADA 141-080, sponsor Pfizer Inc., CDS indication approved 10 December 1998 as a supplement to the original 30 May 1997 approval; 2, 5, 10, 15 and 30 mg tablets; Rx. Selegiline is the levorotatory form of deprenyl HCl and acts as a monoamine oxidase B inhibitor, so a drug-interaction review is mandatory before co-prescribing - the pivotal trial specifically excluded dogs on "medications known to interact with Anipryl," and one trial dog on concurrent metronidazole, prednisone and trimethoprim-sulfa developed weakness, confusion, incoordination and seizure-like activity that resolved when all drugs were stopped.

   FDA-approved indication supported by a placebo-controlled, multi-site, dose-ranging clinical field trial plus an open-label dose-confirmation trial (dog). The supporting open-label 641-dog study is uncontrolled and is Tier 3 evidence at best (dog).

   FDA Freedom of Information Summary, ANIPRYL (selegiline hydrochloride) Tablets for use in dogs, NADA 141-080, approval date 10 December 1998; Campbell S, Trettien A, Kozan B. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Ther. 2001;2(1):24-39. PMID 19753696

3. DOGS: change the diet, do not just add a supplement - MCT-enriched therapeutic nutrition

   Ensayo controlado en esta especie

   Two lines of canine evidence support medium-chain triglyceride (MCT) enrichment. In client-owned dogs with CDS signs, 87 dogs were randomised into three arms of 29 (control, 6.5% MCT oil plus a brain protection blend, 9% MCT oil plus the blend) and fed for 90 days: all 6 categories of CDS signs improved significantly (p < 0.05) on the 6.5% MCT diet, and the honest comparator is that the control diet improved in 4 of 6 categories too. The 9% arm only improved in dogs that accepted the diet, which is a palatability warning as much as a dose finding. In colony aged Beagles, 8 months of a 5.5% MCT-supplemented diet produced significantly better performance on most of a cognitive test battery with elevated circulating beta-hydroxybutyrate, supporting the ketone-as-alternative-brain-fuel mechanism. The systematic review across 30 trials found that studies of enriched diets were of higher methodological quality than studies of supplements, that omega-3 fatty acids showed cognitive benefit especially at higher doses, that antioxidants from plant extracts and vitamins E and C alone were less effective but remain necessary to stabilise the omega-3s, and that SAMe, MCTs, homotaurine and apoaequorin "also showed promise." Owner behaviour runs the other way: in 394 owners of dogs with age-related behavioural change, 54% used dietary supplements (most commonly fish oil, 48%) but only 8% changed the base diet - a direct mismatch with where the evidence is stronger.

   Productos nombrados: Not a drug. Therapeutic diets and supplements are not FDA-approved drugs and no diet may be marketed as treating or preventing dementia. Describe the nutrient composition (MCT percentage, omega-3 dose, B vitamins, antioxidants, arginine), not a disease claim.

   One 90-day prospective double-blinded placebo-controlled clinical study in 87 client-owned dogs with CDS signs, industry-authored (Nestle Purina and CanCog); one 8-month controlled colony-Beagle cognitive-testing study, industry-authored; one systematic review of 30 trials appraised with a modified CAMARADES checklist (all dog).

   Pan Y, Landsberg G, Mougeot I, et al. Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study. Front Nutr. 2018;5:127. PMID 30619873. DOI 10.3389/fnut.2018.00127; Pan Y, Larson B, Araujo JA, et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr. 2010;103(12):1746-54. PMID 20141643. DOI 10.1017/S0007114510000097; Blanchard T, Eppe J, Mugnier A, Delfour F, Meynadier A. Enhancing cognitive functions in aged dogs and cats: a systematic review of enriched diets and nutraceuticals. Geroscience. 2025;47(3):2925-2947. PMID 39827310. DOI 10.1007/s11357-025-01521-z; Haake J, et al. Animals (Basel). 2023;13(19):3056. PMID 37835662. DOI 10.3390/ani13193056

4. CATS: nutritional support exists but the feline evidence is two trials, in healthy older cats, not in cats with diagnosed dementia

   Evidencia preliminar

   The one identifiable feline intervention trial fed middle-aged and old cats (5.5 to 8.7 years) a base diet with or without a blend of antioxidants, arginine, B vitamins and fish oil, after assignment to cognitively equivalent groups on baseline testing. The supplemented cats performed significantly better on 3 of 4 cognitive test protocols (egocentric learning, discrimination and reversal learning, and acquisition of a spatial memory task). Two things must be said on the same page every time. First, these were middle-aged and old cats undergoing laboratory cognitive testing - not client-owned cats with a clinical diagnosis of FCD - so this is evidence for supporting brain ageing, not evidence for treating feline dementia. Second, the systematic review of 30 cognition trials in ageing pets found only 2 feline trials against 27 canine ones, so every feline cognitive-support claim PetSmartMeds makes is standing on canine data and must say so in the same sentence. There is no approved dietary or pharmaceutical intervention for cognitive dysfunction in cats anywhere in the world.

   Productos nombrados: None approved. A 2010 review states plainly "the absence of any approved dietary or pharmaceutical interventions for cognitive dysfunction" in cats. Any pharmacological attempt in a cat is extra-label, is the prescribing veterinarian's decision, and must never be framed on a website as established care.

   One controlled colony/laboratory cognitive-testing trial in cats, industry-authored (Nestle Purina), in cats without a clinical FCD diagnosis; plus a systematic review documenting that only 2 of 30 trials in the field were feline (cat).

   Pan Y, Araujo JA, Burrows J, et al. Cognitive enhancement in middle-aged and old cats with dietary supplementation with a nutrient blend containing fish oil, B vitamins, antioxidants and arginine. Br J Nutr. 2013;110(1):40-9. PMID 23211671. DOI 10.1017/S0007114512004771; Landsberg GM, Denenberg S, Araujo JA. Cognitive dysfunction in cats: a syndrome we used to dismiss as 'old age'. J Feline Med Surg. 2010;12(11):837-48. PMID 20974401. DOI 10.1016/j.jfms.2010.09.004; Blanchard T, et al. Geroscience. 2025;47(3):2925-2947. PMID 39827310. DOI 10.1007/s11357-025-01521-z

5. Environmental management, enrichment and a predictable routine - the intervention with the best cost-to-benefit ratio

   Ensayo controlado en esta especie

   Practical, specific, and free: keep furniture and litter-box positions unchanged; add night lighting along the route to water and the litter box or garden; swap to low-sided, larger litter boxes and add one on every floor for cats; add ramps or non-slip runners; feed, walk and settle at the same times each day; keep short, low-stress training or food-puzzle sessions going during the day to load the sleep-wake cycle in the right direction; block access to stairs, pools and gaps behind furniture where a disoriented pet gets stuck. In aged dogs, the combination of behavioural enrichment and an antioxidant-fortified diet raised temporal-cortex BDNF mRNA toward young-animal levels, while either intervention alone gave intermediate levels, and BDNF correlated positively with cognitive performance and inversely with cortical amyloid-beta - a mechanistic reason to pair enrichment with nutrition rather than choosing one. Be honest about ceiling effects: a 5-week structured group-training programme in 42 dogs with mild-to-moderate CCD did not move CADES scores at all ("CCD scores remained stable across all phases, suggesting no measurable cognitive changes"), so enrichment should be sold as function, safety and quality of life, not as reversal of dementia.

   Productos nombrados: Not a drug intervention.

   Controlled colony study with molecular endpoints in aged dogs (dog); guideline-level recommendation for environmental management of the senior pet (dog and cat); one 5-week prospective study of 42 dogs with mild-to-moderate CCD reporting no change in the cognitive score (dog, honest negative).

   Fahnestock M, Marchese M, Head E, et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging. 2012;33(3):546-54. PMID 20447733. DOI 10.1016/j.neurobiolaging.2010.03.019; Taylor TL, Tuke J, Fernandez EJ, Hazel SJ. Group training classes for dogs with canine cognitive dysfunction: effects on sleep, activity, and caregiver burden. Geroscience. 2026. PMID 42126808. DOI 10.1007/s11357-026-02309-5; Dhaliwal R, et al. J Am Anim Hosp Assoc. 2023;59(1):1-21. PMID 36584321. DOI 10.5326/JAAHA-MS-7343

6. Treat comorbid pain - with species-correct drugs, never carried across species

   Aprobado / respaldado por guías

   Pain is the most common confounder and the most common untreated cause of the behaviours owners report as dementia. In cats, the anti-nerve-growth-factor monoclonal antibody frunevetmab (Solensia) is FDA-approved to control OA pain, with honestly modest effect sizes in the pivotal RCT of 275 cats (number needed to treat 9 and standardised effect size 0.3 on the Client Specific Outcome Measures at day 56) and a disclosable adverse-event signal of skin disorders (32/182 treated vs 8/93 placebo) plus a published case series of five cats with moderate-to-severe pruritus and self-trauma after injection. Feline NSAID use must follow the 2024 ISFM/AAFP consensus: feline-specific drug, feline-specific dose, pre-prescription screening and attention to CKD, which is common in this age group. In dogs, the corresponding biologic is bedinvetmab (Librela, FDA-approved 5 May 2023) and the approved canine NSAIDs are carprofen, meloxicam, deracoxib and firocoxib plus grapiprant. No canine product or dose on this list may be used in a cat.

   Productos nombrados: Cats: frunevetmab (Solensia), NADA 141-546, approved 13 January 2022, the first monoclonal antibody FDA-approved for any animal species; meloxicam and robenacoxib (Onsior) per label and geography - the US robenacoxib label is for postoperative pain and inflammation for a maximum of 3 days, not chronic OA. Dogs: bedinvetmab (Librela); carprofen, meloxicam, deracoxib, firocoxib, grapiprant. Never acetaminophen in a cat, at any dose, in any formulation.

   FDA-approved indications in the respective species, with RCT support of modest effect size in cats; consensus guideline for long-term feline NSAID use (cat); FDA approval plus consensus pain guidelines in dogs (dog).

   Gruen ME, Myers JAE, Tena J-KS, et al. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats. J Vet Intern Med. 2021;35(6):2752-2762. PMID 34724255. DOI 10.1111/jvim.16291; Taylor S, Gruen M, KuKanich K, et al. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J Feline Med Surg. 2024;26(4). PMID 38587872. DOI 10.1177/1098612X241241951; Storrer A, Mackie JT, Gunew MN, Aslan J. Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections. J Feline Med Surg. 2023;25(11). PMID 37975186. DOI 10.1177/1098612X231198416

7. DOGS: S-adenosylmethionine (SAMe) as an adjunct, with its limits stated

   Ensayo controlado en esta especie

   In a double-blinded, placebo-controlled trial, 36 dogs older than 8 years with at least one month of cognitive dysfunction signs received SAMe tosylate 18 mg/kg (n = 17) or identical placebo (n = 19) for 2 months, with concurrent behavioural treatment forbidden. SAMe-treated dogs improved more than placebo in activity (57.1% vs 9.0% at 8 weeks, P < 0.003) and awareness (59.5% vs 21.4% at 8 weeks, P < 0.01), and the aggregate mental impairment score fell by more than 50% in 41.2% of SAMe dogs versus 15.8% of placebo dogs. The limits: n = 36, a 14-item owner questionnaire as the only outcome, 8 weeks of follow-up, and authorship from the manufacturer's medical department. The systematic review lists SAMe among supplements that "showed promise," which is the correct strength of claim. There is no feline SAMe cognition trial.

   Productos nombrados: S-adenosylmethionine (SAMe) tosylate, marketed as a veterinary nutraceutical, not an approved drug. Do not present it as approved therapy.

   One randomised, double-blinded, placebo-controlled trial, n = 36, owner-questionnaire outcome, industry-authored (dog). No feline data located.

   Reme CA, Dramard V, Kern L, Hofmans J, Halsberghe C, Vida Mombiela D. Effect of S-adenosylmethionine tablets on the reduction of age-related mental decline in dogs: a double-blinded, placebo-controlled trial. Vet Ther. 2008;9(2):69-82. PMID 18597245

8. Caregiver support, quality-of-life tracking and an explicit end-of-life plan

   Aprobado / respaldado por guías

   Night waking, vocalisation and house-soiling are the signs that break households, and caregiver burden is a legitimate clinical endpoint in this disease - the canine group-training study measured it alongside sleep and activity for exactly that reason. Set expectations at the first consultation: CDS is progressive, the goal is function and comfort rather than reversal, and treatments are judged over months, not days. The 2023 AAHA Senior Care Guidelines include palliative and hospice care and client education as part of senior care, and the 2021 AAFP feline guidelines address quality of life, budgets of care and euthanasia decision-making directly. Agreeing in advance on what a bad week looks like is kinder than deciding in a crisis at 3 a.m.

   Guideline-level recommendation in both species; caregiver-burden instruments used as endpoints in a canine CCD study (dog and cat).

   Dhaliwal R, et al. 2023 AAHA Senior Care Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2023;59(1):1-21. PMID 36584321. DOI 10.5326/JAAHA-MS-7343; Ray M, et al. 2021 AAFP Feline Senior Care Guidelines. J Feline Med Surg. 2021;23(7):613-638. PMID 34167339. DOI 10.1177/1098612X211021538

9. Emerging and not yet standard of care - senolytic plus NAD+ precursor, depot donepezil, faecal microbiota transplantation

   Evidencia preliminar

   Three canine signals exist and none of them changes practice yet. (1) Senolytic plus NAD+ precursor combination (LY-D6/2): 70 dogs with mild-to-moderate cognitive impairment randomised to placebo, low or full dose; a significant between-group difference in owner-reported CCDR score at the 3-month primary endpoint (p = 0.02), largest in the full-dose group. But there was NO difference on in-house cognitive testing and NO difference in accelerometer-measured activity, the authors state "All groups showed improvement in cognition, frailty, and activity suggesting placebo effect and benefits of trial participation," and the intervention was a combination so nothing can be attributed to NAD+ alone. The trial used an ORAL product; injectable or nasal NAD+ at 500-1000 mg has no canine or feline data at any dose. (2) Long-acting intramuscular donepezil depot: 32 dogs randomised to high dose, low dose or control, with significant improvement in CCDR, CADES and DISHAA in the high-dose group at days 14 and 28 and lower serum neurofilament light chain in both treated groups at day 28; 28 days of follow-up, n = 32, pharmaceutical-company co-authorship, and no regulatory approval anywhere. (3) Faecal microbiota transplantation: 11 dogs, open-label, no control; only 6 dogs had complete 90-day DISHAA data, of whom 4 improved and 2 worsened. That is hypothesis-generating and nothing more. None of the three has any feline data.

   Productos nombrados: LY-D6/2 (senolytic plus NAD+ precursor, investigational, oral); donepezil depot injection (investigational, not approved for animals in any jurisdiction); faecal microbiota transplant capsules (not an approved drug). None may be presented as treatment.

   One randomised controlled trial with a positive owner-reported endpoint and negative objective endpoints (dog); one small randomised 28-day industry-affiliated trial (dog); one uncontrolled 11-dog pilot (dog). No feline data for any of them.

   Simon KE, Russell K, Mondino A, et al. A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination. Sci Rep. 2024;14(1):12399. PMID 38811634. DOI 10.1038/s41598-024-63031-w; Kang MH, Kang MA, Jeon HJ, et al. Evaluation of the safety and efficacy of a donepezil depot injection in dogs with canine cognitive dysfunction. Front Vet Sci. 2025;12:1724060. PMID 41473097. DOI 10.3389/fvets.2025.1724060; Dewey CW, Rojas CA, Pomeroy C, Gerardi J, Ganz HH. Fecal microbiota transplantation shows promise in slowing or reducing cognitive impairment in aging dogs. J Am Vet Med Assoc. 2026. PMID 42269666. DOI 10.2460/javma.26.03.0231

Cómo se diagnostica

• Take a structured behavioural history first, ideally on a scored owner questionnaire - CADES or CCDR in dogs, and the DISHAA framework (disorientation, interaction changes, sleep-wake changes, house soiling, activity change, anxiety) to make sure all six domains are asked about. CDS is a clinical diagnosis of exclusion built on documented change over time, not a test result (Dondi M et al. Animals (Basel). 2026;16(7):1114. PMID 41976093. DOI 10.3390/ani16071114).
• Full physical and neurological examination including deliberate assessment of vision and hearing. Sensory decline reproduces disorientation, unresponsiveness and startle-aggression, and it is common in exactly the age group in question.
• Minimum database: CBC, serum biochemistry, urinalysis and indirect blood pressure. The 2021 AAFP Feline Senior Care Guidelines include blood pressure assessment as a minimum diagnostic procedure in both apparently healthy and ill senior cats (PMID 34167339, DOI 10.1177/1098612X211021538).
• Cats specifically: total T4, because apparent hyperthyroidism prevalence is 8.7% in cats 10 years and older and drives restlessness, vocalisation and night activity (PMID 25028466); and renal staging, because CKD prevalence was 50% in a randomly age-stratified feline cohort and 68.8% in cats recruited for degenerative joint disease studies (PMID 24217707, DOI 10.1177/1098612X13511446).
• Deliberate pain and orthopaedic assessment in both species, and especially in cats. In 100 cats aged 6 years and older, increased inappropriate elimination was significantly associated with osteoarthritis (P = 0.046), and cats with OA usually do not limp - an arthritic cat may simply be unable to climb into a high-sided litter box (PMID 20083417, DOI 10.1016/j.tvjl.2009.12.014).
• Dogs specifically: consider endocrine testing for hypothyroidism and hyperadrenocorticism, and hepatic evaluation, where the history or bloodwork points that way. The Anipryl field trial excluded dogs with concurrent debilitating disease or drugs that could affect behaviour precisely because these confound the assessment (FDA FOI Summary, NADA 141-080).
• Advanced imaging (MRI) where onset was rapid, progression is fast, signs are asymmetric or lateralising, or seizures are present - to exclude intracranial neoplasia and cerebrovascular disease. Fluid biomarkers are promising but not clinical tests: plasma neurofilament light chain correlated with CADES score (r = 0.41, p = 0.025) in 39 aging pet dogs and with inhibitory control performance (r = -0.7, p <= 0.001), and remains a research measure (PMID 35431246, DOI 10.3233/JAD-215562).